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Abstract
Genome-wide association studies (GWAS) have become increasingly common due to advances in technology and have
permitted the identification of differences in single nucleotide polymorphism (SNP) alleles that are associated with diseases.
However, while typical GWAS analysis techniques treat markers individually, complex diseases (cancers, diabetes, and
Alzheimers, amongst others) are unlikely to have a single causative gene. Thus, there is a pressing need for multi-SNP analysis
methods that can reveal system-level differences in cases and controls. Here, we present a novel multi–SNP GWAS analysis
method called Pathways of Distinction Analysis (PoDA). The method uses GWAS data and known pathway–gene and gene–
SNP associations to identify pathways that permit, ideally, the distinction of cases from controls. The technique is based upon
the hypothesis that if a pathway is related to disease risk, cases will appear more similar to other cases than to controls (or vice
versa) for the SNPs associated with that pathway. By systematically applying the method to all pathways of potential interest,
we canidentifythose for which the hypothesis holds true,i.e., pathways containingSNPs forwhich thesamplesexhibit greater
within-class similarity than across classes. Importantly, PoDA improves on existing single–SNP and SNP–set enrichment
analyses, in that it does not require the SNPs in a pathway to exhibit independent main effects. This permits PoDA to reveal
pathways in which epistatic interactions drive risk. In this paper, we detail the PoDA method and apply it to two GWAS: one of
breast cancer and the other of liver cancer. The results obtained strongly suggest that there exist pathway-wide genomic
differences that contribute to disease susceptibility. PoDA thus provides an analytical tool that is complementary to existing
techniques and has the power to enrich our understanding of disease genomics at the systems-level.
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Introduction
Genome-wide association studies (GWAS) have become a
powerful and increasingly affordable tool to study the genetic
variants associated with disease. Modern GWAS yield information
on millions of single nucleotide polymorphism (SNPs) loci
distributed across the human genome, and have already yielded
insights into the genetic basis of complex diseases [1,2], including
diabetes, inflammatory bowel disease, and several cancers [3–7]; a
complete list of published GWAS can be found at the National
Cancer Institute–National Human Genome Research Institute
(NCI-NHGRI) catalog of published genome-wide association
studies [8].
Typically, the data produced in GWAS are analyzed by
considering each SNP independently, testing the alleles at each
locus for association with case status; significant association is
indicative of a nearby genetic variation which may play a role in
disease susceptibility. Genomic regions of interest may also be
subject to haplotype analysis, in which a handful of alleles
transmitted together on the same chromosome are tested for
association with disease; in this case, the loci which are jointly
considered are located within a small genomic region, often
confined to the neighborhood of a single gene.
Recently, however, there has been increasing interest in
multilocus, systems-based analyses. This interest is motivated by
a variety of factors. First, few loci identified in GWAS have large
effect sizes (the problem of ‘‘missing heritability’’) and it is likely
that the common–disease, common–variant hypothesis [9,10] does
not hold in the case of complex diseases. Second, single marker
associations identified in GWAS often fail to replicate. This
phenomenon has been attributed to underlying epistasis [11], and
a similar problem in gene expression profiling has been mitigated
through the use of gene-set statistics. Most importantly, it is now
well understood that because biological systems are driven by
complex biomolecular interactions, multi-gene effects will play an
important role in mapping genotypes to phenotypes; recent
reviews by Moore and coworkers describe this issue well [10,12].
Additionally, the finding that epistasis and pleiotropy appear to be
inherent properties of biomolecular networks [13] rather than
isolated occurences motivates the need for systems-level under-
standing of human genetics.
The impact that biological interaction networks have on our
ability to identify genomic causes of complex disease is readily
apparent. Consider a biologically crucial mechanism with several
potential points of failure, such that an alteration to any will confer
disease risk. Because no single alteration is predominant amongst
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observed that even in histologically identical tumors, only a
fraction may share the same set of mutations (see references in [14]
for examples). Additionally, in a robust system, multiple alterations
may be necessary to alter the activity of an interaction network;
here, healthy individuals may share a subset of the deleterious
alleles found in cases, and again these loci will not be detected.
This complexity, noted by [10,12–14] and others, has generated
considerable interest in multi-locus analysis techniques that take
advantage of known interaction information.
Several multi-SNP GWAS analysis approaches have been
described in the literature. Thorough reviews are provided in
[15,16], and we briefly describe several here. Building on the well-
established Gene Set Enrichment Analysis [17] method initially
developed for gene expression data, two articles have proposed an
extension of GSEA for SNP data [18,19]. In these techniques,
each SNP is assigned a statistic based on a x2 test of association
with the phenotype; a running sum is then used to assess whether
large statistics occur more frequently amongst a SNP set of interest
than could be expected by chance. While GSEA-type approaches
have proven quite useful, their reliance on single-marker statistics
means that systematic yet subtle changes in a gene set will be
missed if the individual genes do not have a strong marginal
association. In the case of a purely epistatic interaction between
two SNPs in a set, the set may fail to reach significance altogether.
To address this issue, Yang and colleagues proposed SNPHar-
vester [20], designed to detect multi-SNP associations even when
the marginal effects are weak. To reduce the search space of
possible multi-SNP effects, SNPHarvester [20] first removes any
SNPs with univarite significance. Using a novel searching
algorithm, they identify groups of l SNPs that show association
with status in a x2 test with 3l{1 degrees of freedom. While this
approach can reveal epistatic effects that would be missed by the
GSEA-type schemes [18,19], it has other drawbacks. First, the
combinatorial explosion of SNP groups puts a limit on the number
of SNPs l that may simultaneously be examined. Second, the the
arbitrary groupings of SNPs and the exclusion of SNPs with
marginal effects can make the biological interpretation of the
analysis results difficult.
The notion that cases will more closely resemble other cases
than they will controls has motivated a number of interesting
distance-based approaches for detecting epistasis. Multi-dimen-
sionality reduction (MDR) has been proposed and applied to SNP
data [21–23]. In this technique, sets of l SNPs are exhaustively
searched for combinations that will best partition the samples by
examining the 3l cells in that space (corresponding to homozygous
minor, heterozygous, or homozygous major alleles for each locus)
for overrepresentation of cases. While this method both finds
epistatic interactions without requiring marginal effects and can be
structured to incorporate expert knowledge, it is limited by the fact
the the total number of loci to be combinatorially explored must
be restricted to limit computational cost. To address this, an
‘‘interleaving’’ approach in which models are constructed
hierarchically has been suggested [22] to reduce the combinatorial
search space. A recent and powerful MDR implementation [24]
taking advantange of the CUDA parallel computing architecture
for graphics processors has made feasible a genome-wide analysis
of pairwise SNP interactions. Still, MDR remains computationally
challenging, such that expanding the search to other SNP set sizes
(rather than restricting to pairwise interactions) can be impeded by
combinatorial complexity if an exhaustive search is to be
performed.
In order to narrow down the combinatorial complexity of
discovering SNP sets using techniques such as MDR, feature
selection may be employed. Of particular importance here is the
distance-based approach of the Relief family of algorithms [25–
28]. These are designed to identify features of interest by weighting
each feature through a nearest-neighbor approach. The weights
are constructed in the following way: for each attribute, one selects
samples at random and asks whether the nearest neighbor (across
all attributes) from the same class and the nearest neighbor from
the other class have the same or different values from the
randomly chosen sample. Attributes for which in-class nearest
neighbors tend to have the same value are weighted more strongly.
Because the distances are computed across all attributes, Relief-
type algorithms can identify SNPs that form part of an epistatic
group and they provide a means of filtration that does not have the
drawbacks of other significance filters.
While these methods have so far been applied to finding small
groups of interacting SNPs, one may instead be interested in
whether cases and controls exhibit differential distance when
considering a large number of genes. A multi-SNP statistic has
been proposed in the literature [29–31] for determining whether
an individual of interest is on average (across a large number of
SNPs) ‘‘closer’’ to one population sample than to another. The
method, originally proposed by Homer [29], is motivated by the
idea that a subtle but systematic variation across a large number of
SNPs can produce a discernible difference in the closeness of an
individual to one population sample relative to another. While this
statistic was originally designed to identify the proband as a
member of one of the population samples, it was shown in [30]
that out-of-pool cases from a case-control breast cancer study were
in general closer (as defined by the statistic presented in [29]) to in-
pool cases than they were to in-pool controls, suggesting that the
combination of multiple alleles has the potential to distinguish
cases from controls.
Building on these ideas, we present a new technique that finds
pathway-based SNP-sets that differentiate cases from controls; we
call this method Pathways of Distinction Analysis (PoDA). In
PoDA, SNP sets are defined based on known relationships (e.g.,
SNPs in genes sharing a common pathway), and thus incorporate
expert knowledge to reduce the search space and provide
biological interpretability. Motivated by the differential ‘‘close-
ness’’ of cases and controls as discussed about and as observed in
[30], we hypothesize that if the SNPs come from a pathway that
plays a role in disease, there will be greater in-class similarity than
across-class similarity in the genotypes for those SNPs; i.e., a case
will show greater genetic similarity to other cases than to controls
for the SNPs on a disease-related pathway, but will be equidistant
Author Summary
We present a novel method for multi–SNP analysis of
genome-wide association studies. The method is motivat-
ed by the intuition that, if a set of SNPs is associated with
disease, cases and controls will exhibit more within-group
similarity than across-group similarity for the SNPs in the
set of interest. Our method, Pathways of Distinction
Analysis (PoDA), uses GWAS data and known pathway–
gene and gene–SNP associations to identify pathways that
permit the distinction of cases from controls. By system-
atically applying the method to all pathways of potential
interest, we can identify pathways containing SNPs for
which the cases and controls are distinguished and infer
those pathways’ role in disease. We detail the PoDA
method and describe its results in breast and liver cancer
GWAS data, demonstrating its utility as a method for
systems-level analysis of GWAS data.
Pathways of Distinction Analysis
PLoS Genetics | www.plosgenetics.org 2 June 2011 | Volume 7 | Issue 6 | e1002101for the SNPs on a non-disease-related pathway. Based on this
notion, PoDA seeks to identify pathways for which differential
heterogeneity is exhibited in cases and controls. In each pathway,
PoDA returns a statistic S for each sample that quantifies that
sample’s distance to the remaining cases relative to its distance to
the remaining controls for a given pathway’s SNPs. PoDA then
examines whether the distributions of S for the controls differ from
those of the cases by computing and testing for significance a
Pathway Distinction Score DS that quantifies the differences in
case and control S distributions. In this manuscript, we detail the
PoDA method and report the results of its application to two data
sets.
As we will describe, PoDA improves and complements existing
approaches in a number of respects. First, it permits the
investigation of arbitrarily large pathways, circumventing the
dimensionality issues that are encountered with MDR and SNP-
Harvester. Second, it is able to detect pathways that contain an
over-abundance of highly-significant markers as well as pathways
whose markers have a small but consistent association that would
be missed by GSEA-type approaches. Finally, it uses a leave-one-
out technique to return for each sample an unsupervised relative
distance statistic that can then be used to model disease risk via
logistic regression. In addition to providing an effect size for the
pathway, this allows the odds of disease for new samples to be
obtained by computing its relative distance statistic with respect to
the known samples and applying the model.
Methods
Following our conjecture that SNPs associated with the genes in
a pathway involved in disease will exhibit more within-group
similarity than across-group similarity, we propose Pathways of
Distinction Analysis (PoDA), a method designed to address the
following questions:
N Given some set of SNPs, do we find that, on average, cases are
‘‘closer’’ to other cases than to controls (or that controls are
‘‘closer’’ to other controls than to cases)?
N If we look for these distinctions systematically over all SNP-sets
of potential interest, can we use it to single out SNP-sets which
may be associated with disease?
In PoDA, a set of SNPs are selected, and for each sample we
compute whether it is closer to the pool of remaining cases or
controls across that SNP set, using the relative distance statistic
described below. Once this is done for every sample, the
distribution of the relative distance statistic is compared in the
cases and controls using a nonparametric statistic, addressing the
first question above. This may be carried out amongst all SNP sets
of interest, adjusting the p-value for the multiple hypotheses, to
find SNP sets for which cases more strongly resemble the
population of remaining cases while controls more strongly
resemble the population of remaining controls.
We begin with a discussion of how we measure the relative
distance of an individual to the other cases vs. other controls. A
simple but computationally intensive approach is to represent each
sample by a vector in an l-dimensional space, where l is the
number of SNPs in the group of interest. One can then compute,
between each sample pair, their distance in this l-dimensional
space using a Euclidean, Manhattan, or Hamming metric. For
each sample, we would define its relative distance statistic as the
mean of its distance to other controls minus the mean of its
distance to other cases; a sample that is more similar to cases will
exhibit a positive statistic, whereas one that is more similar to other
controls will exhibit a negative statistic. For the given SNP set, we
would then have for each sample a value quantifying its relative
distance that was computed without knowledge of that sample’s
class (i.e., using a leave-one-out scheme) and could then be used in
further tests. By doing this for all pathways of interest, one derives
a relative distance value for each sample in each pathway.
This brute-force approach, while conceptually clear, has two
significant drawbacks. The first is that the distance computation is
O(l:n2) where n is the total number of samples in the study–a
considerable undertaking, particularly if many SNP sets are to be
analyzed, and one that becomes exceedingly troublesome in the
context of permutation tests. The second drawback is that because
we are taking the mean of the distances, a sample that is situated
squarely within a cluster of cases may have a large case-distance
value due to the dispersion of cases around it. Both of these issues
are circumvented by instead considering the relative distance to
the centroids of the cases and controls in the l-dimensional space, a
computation that can be performed in O(l:n) for all n samples. It is
this approach that PoDA employs, as follows:
In [29,30], the authors consider a measure of individual Y’s
distance to two population samples F and G at locus i,
DY,i~ yi{fi jj { yi{gi jj : ð1Þ
where fi and gi are the minor allele frequencies (MAFs) of SNP i in
samples F and G, and yi [ f0,0:5,1g is Y’s genotype at i
corresponding to homozygous major, heterozygous, and homozy-
gous minor alleles, respectively (i.e., the frequency of minor allele
in that individual. The first term quantifies how different Y’s MAF
is from F’s for a given locus i; the second term quantifies how
different Y’s MAF is from G’s at locus i; and so DY,i gives the
distance of Y relative to F and G at locus i. Since the minor allele
frequencies fi and gi are computed by averaging the genotypes
(again, written as f0,0:5,1g) in samples F and G respectively, it is
clear that yi{fi jj is the distance from Y to the centroid of F along
the coordinate i (and likewise for the gi term). It can be seen from
Eq. 1 that positive DY,i implies that yi is closer to gi than to fi, and
that negative DY,i implies that yi is closer to fi than to gi.
By computing DY,i at each locus i and taking the standardized
mean across the l loci, [29] obtain a distance score S which
quantifies how close Y is relative to F and G across all l loci under
consideration,
SY~
E(DY,i)
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Var(DY,i)=l
p , ð2Þ
where E(DY,i) denotes the mean of DY,i across all loci i. That is, S
provides a means to quantify whether Y’s MAFs are closer to G’s
MAFs or F’s MAFs on average for the loci under consideration. It
is instructive to consider the geometrical interpretation of Eq. 2. Is
clear upon inspection that the numerator in Eq. 2 is equal, up to a
factor of l, to the difference in Manhattan distances between Y
and the (nonstandardized) G centroid and Y and the (nonstan-
dardized) F centroid; in this sense, Eq. 2 resembles a nearest-
centroid classifier. However, the denominator scales the relative
distances by their variance across the l SNPs; that is, a sample Y
who is consistently closer to G than to F for each of the l SNPs will
obtain a higher S than an individual who is variously closer to
either across the l SNPs under consideration.
By assigning the (non-Y) controls as F and the (non-Y) cases as
G, we can compute a statistic SY quantifying Y’s distance to other
cases relative to Y’s distance to other controls. If we then apply
this systematically to all individuals in the study population
(removing that individual, computing the MAF’s fi and gi for the
Pathways of Distinction Analysis
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computing SY in a leave-one-out manner), we can obtain
distributions of SY statistics in cases and controls that may be
compared. Here, the null hypothesis is that case and control SY
distributions do not differ, with the alternative hypothesis that the
cases have higher S values than do controls, i.e., that they are
closer (via Eqs. 1–2) to other cases than are controls.
We can use S in the following manner to answer the questions
posed above by applying it in a leave-one-out manner in each
pathway:
1. For a given pathway P, select the lP SNPs associated with that
pathway;
2. For every sample Y, remove Y from the case or control group
as needed, and compute SY,P with respect to the remaining
cases and controls using the SNPs chosen in step 1.
3. Quantify the differences in distribution of SY,P’s for the case
samples versus that of the controls and test for significance.
By systematically carrying out the above steps on all pathways of
interest, we can identify pathways for which there appears to be
differential homogeneity in cases and controls, indicating that the
pathway may play a disease-related role. The details of the
algorithm are explained below, and summarized in Table 1.
In [30], we examined Eqs. 1–2 and found that the magnitude of
S is influenced both by the MAF differences fi{gi (that is, how
distant the centroids of F and G are) and by correlations between
the SNPs under consideration (due to the penalization for variance
in Di provided by the denominator of Eq. 2. These properties are
extremely well-suited to the application we propose: pathways with
few highly-significant SNPs will yield large S differences (due to
the influence of fi{gi), as will pathways with SNPs that are highly
correlated yet have subtle individual MAF differences, corre-
sponding to the concerted action of multiple SNPs.
At the same time, however, we wish to ensure that the pathways
we select as having differential S are not being influenced large LD
blocks covered by the SNPs in the genes on the pathway. That is,
we wish to ensure that the SNP correlations which drive S are
reflective of epistatic effects between different genes rather than
recombination events within a gene. To this end, we select a single
SNP to represent each gene, based on the desire to detect multi-
gene rather than multi-SNP effects.
In practice, SNPs are selected as follows: for each pathway
represented in the Pathway Interaction Database [32] (PID,
http://www.pid.nci.gov, containing annotations from BioCarta,
Reactome, and the NCI/Nature database [32]) and KEGG [33],
we select the associated genes. Using dbSNP [34], we retrieve the
SNPs associated with the pathway genes that are present in the
data, excluding those with w20% missing data or with minor
allele frequency v0:05 in either case of control group. We
necessarily exclude pathways for which only one gene is probed by
the remaining SNPs. Because we are interested in S values that are
driven by correlations across genes (and not in individual genes
covered by many SNPs with high LD), we select for each gene its
most significant SNP in a univariate test of association (Fisher’s
exact test). It should be noted here that while the SNP chosen for
each gene is the most significant of that gene’s SNPs, it is not
necessarily significantly associated with disease. Our goal here is
not to filter based on SNP significance, but rather to select, for
each gene, a single marker that is as informative as possible.
Having selected the SNPs of interest, we compute DY,i at each
locus for every sample by selectively removing it and comparing it
to the remaining cases and controls, as described above. For each
pathway P, we compute SY,P for lP the SNPs i that comprise it,
yielding a distribution of SY,P for cases and another distribution
for controls. The difference in the location of the case and control
SY,P distributions is then quantified nonparametrically by
computing the Wilcoxon rank sum statistic, defined as
WP~
X
Y[case
RY,P{
ncase(ncasez1)
2
ð3Þ
where RY,P is the rank of SY,P amongst all samples Y for a given
pathway P. Eq. 3 thus quantifies, non-parametrically, the degree
to which cases are ‘‘closer’’ to other cases and controls ‘‘closer’’ to
other controls across a set of SNPs for all individuals in the
GWAS.
To illustrate the above, we consider a simulated GWAS of 250
cases and 250 controls and 50 SNPs, shown in Figure 1, and ask
whether we are able to detect a 12-SNP pathway in which a subset
of SNPs appear to have an epistatic interaction. Alleles were
simulated as binomial samples from a source population with
MAFs ranging from 0.1 to 0.4 across the 50 SNPs, and case labels
were assigned such that a combintion of homozygous minor alleles
at SNPs 1 and 2 or 3 (i.e., (y1~1) ^ ((y2~1) _ (y2~1)))
conferred a three-fold relative risk, mimicking an epistatic
interaction between SNPs 1 and 2 and SNPs 1 and 3 (Figure 1a).
Alone, none of the 50 SNPs showed any association with case
status, nor was any SNP significantly out of HWE in either cases or
controls. However, the ‘‘shared pattern’’ in SNPs 1–3 is such that a
12 SNP pathway comprising SNPs 1–12 yields greater S in cases
than in controls as can been seen in Figure 1b, while a random 12
SNP pathway selected from the 50 SNPs (that includes SNP 3, but
neither SNP 1 or 2) shows no difference in S values as seen in
Figure 1c.
While the Wilcoxon statistic W is normal in the large-sample
limit and can be directly compared to a Gaussian, to truly evaluate
Table 1. Procedure for Pathways of Distinction Analysis.
1. For a each pathway P, select all associated genes from pathway database such as PID [32];
2. For each gene on the pathway, select associated SNPs (e.g., using dbSNP) and choose the one with the strongest association with case status,
determined using Fisher’s exact test;
3. For each sample Y in the GWAS, select the controls F and cases G which do not include it, compute MAFs fi and gi for the SNPs i selected in
step 2, and compute SY,P for each sample Y;
4. Compare the distribution of SY,P obtained in step 2 for cases to that of controls by computing the Wilcoxon statistic WP based on
the SY,P for that pathway;
5. Repeat steps 2–5 using permuted case/control labels, and normalize WP by the distribution of W 
P obtained with permuted labels, yielding the
distinction score DSP;
6. Compare the distinction score DSP obtained in step 5 to that obtained for random sets of lP genes, where lP is the number of genes in
the pathway of interest.
Pathways of Distinction Analysis
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sources of bias: the number of SNPs per gene, and the size of the
pathway. To address these issues, we introduce a normalized
Pathway Distinction Score DSP that we test for significance using
a resampling procedure.
First, we expect that because we have selected for each gene the
single most informative SNP, we are pre-disposed to seeing higher
WP for pathways that contain large genes. Because large genes will
be more likely to contain highly-significant SNPs by chance, the
concern has been raised that [18,35] selecting the single most
significant SNP as a proxy for the gene (as is done here) will lead to
a bias toward pathways that contain an abundance of large genes.
To account for this, we follow the approach in [18] and normalize
the score via a permutation-based procedure. First, we permute
the phenotype labels and in each permutation recalculate WP as
described above, but using the permuted case and control labels.
The permuted labels are used both to select the most informative
SNP per gene and to compute fi, gi, and WP in Eqns. 1–3). This
yields a distribution of W 
P under the null hypothesis that the
magnitude of W is independent of the true case/control
classifications. We then normalize the true WP by the distribution
from the permutation procedure, yielding a Distinction Score DSP
for pathway P that effectively adjusts for different sizes of genes
and preserves correlations of SNPs in the same gene:
DSP~
WP{E(W 
P)
SD(W 
P)
, ð4Þ
where W 
P are the set of WP obtained for pathway P across the
permutations. (In practice, 100 permutations are used.) Because
the permuted labels are used in the SNP selection, this
normalization adjusts for the bias introduced by the fact that
large genes have more opportunity to contain significant SNPs by
chance. The Pathway Distinction Score DSP thus provides a
model-free, gene-size adjusted metric for quantifying the degree to
which cases are ‘‘closer’’ to other cases (higher SP) than controls.
To test whether DSP is significant, we note that larger pathways
may yield high DSP values simply due to the fact that they sample
the case anc control differences more thoroughly. Indeed, the
question of significance that we wish to address is not simply
whether a pathway permits the distinction of cases and controls,
but whether it does so better than a random collection of as many SNPs,
wherein the SNPs are still selected to be the most informative by
gene. To account for the fact that the pathways are of differing
sizes, significance of the Distinction Score for a given pathway is
assessed through resampling by choosing, at random, the same
number of SNPs that are present in that pathway (lP) from the
total set of most-informative-SNP-per-gene and recomputing DSP
for the random pathway. The p value is obtained by counting the
fraction of random lP-SNP sets which give a larger DSP than the
true pathway SNPs in 104 resamplings. In this way, we are able to
detect pathways that yield large differences of case and control S
distributions due to their particular SNPs, rather than simply being
the result of choosing many SNPs. The p value obtained addresses
the question of whether the pathway under consideration permits
Figure 1. PoDA applied to simulated data. Alleles at 50 loci for 250
cases and 250 controls were simulated such that each SNP was in HWE
and not associated with case status, but homozygous minor (red) at
both loci 1 and 2 or 1 and 3 yielded a three-fold relative risk (a). A 12-
SNP pathway comprising SNPs 1–12 shows differential S distributions
(b); a random 12-SNP pathway does not (c). Boxplots are overlayed on
the scatterplots of S for clarity.
doi:10.1371/journal.pgen.1002101.g001
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collection of most-informative-SNP-per-gene, i.e., whether there
exists a more extreme aggregated effect in that pathway than
expected by chance.
Results
We applied PoDA to 2287 genotypes obtained from the Cancer
Genomic Markers of Susceptibility (CGEMS) breast cancer study.
The samples were sourced as described in [4]. Briefly, the samples
comprised 1145 breast cancer cases and a comparable number
(1142) of matched controls from the participants of the Nurses
Health Study. All the participants were American women of
European descent. The samples were genotyped against the
Illumina 550K arrays, which assays over 550,000 SNPs across the
genome.
We also applied it to a smaller liver cancer GWAS [36]
comprising 386 hepatocellular carcinoma (HCC) patients and 587
healthy controls from a Korean population. Samples were
genotyped against Affymetrix SNP6.0 arrays, which provides
SNP information at approximately one million loci.
Breast cancer GWAS results
We begin by applying PoDA to the CGEMS breast cancer
GWAS data. Having observed (Figure 1) that PoDA performs as
expected for the simulated data, we first turn our attention to a
simple test in which we select a SNP set comprising the four SNPs
in intron 2 of FGFR2 that were reported to show significant
association with case status in [4] (rs11200014, rs2981579,
rs1219648, rs2420946). We expect to see a strong difference in
the test case and test control distributions, and indeed we do: the
cases more frequently have positive S than do controls in Figure 2.
(The discrete peaks in the distribution are a result of the fact that
with four SNPs there exist fewer available values of S.) Using a
nonparametric Wilcoxon rank sum test with the alternative
hypothesis that cases have greater S than controls,
p~1:016:10{6 is obtained, confirming our intuition.
We next applied PoDA systematically to the pathways
represented in PID [32] using CGEMS data. Associations between
genes and SNPs were made using dbSNP build 129 [34]. 1081
pathways were non-trivially covered in the data set; 69453 SNPs in
the data could be associated with at least one of the pathways.
Because these 69453 SNPs were associated with 4446 unique
genes, 4446 were kept in the analysis (the most significant SNP for
each gene of interest). The 1081 pathways ranged from 2 to 229
genes, with a mean of 19. SY,P was computed in each pathway P
for each of the 2287 samples Y via Eq. 2, and the distinction score
DSP (Eq. 4) quantifying differential S distributions in cases and
controls was computed for each pathway. Significance was
assessed as described above, by resampling ‘‘dummy’’ pathways
of the same length and computing the fraction of greater DSP
scores.
Because PoDA provides for each sample a measure S (Eq. 2 of
that sample’s relative distance from the remaining ones that is
obtained without regard to that sample’s true class membership,
we can use the S value as a metric by which to predict the odds of
disease. Here, we construct a logistic regression model of case
status as a function of S to obtain the odds ratio. p-values were
adjusted for the multiplicity of pathways using FDR adjustment
[37,38].
Pathways with significant DSP and odds ratios are reported in
Table 2 and plots of S for four of them are illustrated in Figure 3.
Although the cases and controls are not crisply separable, a unit
increase in S over its range from approximately 23 to 3 yields
between a 1.5 and 2.0-fold increase in odds. Importantly, given
known minor allele frequencies for cases and controls for this set of
SNPs, we can model the increase in odds for an unknown
individual based on her ‘‘closeness’’ to other cases.
In order to ensure that the pathways listed were not
interrogating the same set of genes, we carried out two checks.
First, we computed the SNP overlap between all pairs of
significant pathways, sequentially removing pathways that shared
in excess of 60% of their genes with another pathway. Because this
is done using a greedy algorithm that depends on the order of the
pathways input, the culling algorithm was run with different
starting orders, and the most frequent output was kept. No
pathway remaining in Table 2 shares more than 60% of its SNPs
with another pathway. (An un-culled list may be found in Table
S1.) Second, we computed the correlation of S values between
each pair of pathways to assess whether any pathway’s S statistic
was reflecting the same genetic variation as another (i.e., whether
samples that had high S values for one pathway consistently did so
in another). The maximum correlation of S values observed
between any two pathways in Table 2 was 0.58, suggesting that a
different subset of samples is affected in each pathway.
Many of the pathways listed in Table 2 fulfill biological
functions that are well known to be cancer-associated, playing a
strong role in cell proliferation and migration, processes which are
perturbed in malignancies. Purine metabolism–the most signifi-
cantly associated pathway–has been observed to be altered in
cancer cells [39,40], and the majority of the other significant
pathways are directly related to cell migration (e.g., ErbB signaling
and gap junction pathways) and cellular signalling (e.g., calcium
signaling, PKC-catalyzed phosphorylation of myosin phosphatase,
attenuation of GPCR signaling, and activation of PKC through
GPCRs) processes that have been implicated in a variety of
cancers. In addition, eicosanoids and unsaturated fatty acid
metabolism have been associated with breast cancer specifically
[41]. In general, the findings in Table 2 suggest that there exist
germline genetic differences in these mechanisms that confer a
predisposition to disease.
Figure 2. PoDA applied to four highly-significant SNPs. Shown is
the distribution of S values in CGEMS cases (red) and controls (black) for
a SNP-set comprised of four highly-significant SNPs located in the
FGFR2 gene [4]. As expected, there is a substantial difference in case
and control S values, with the cases having higher S (i.e., closer to other
cases) than controls. The discreteness of the distributions are due to the
fact that with four SNPs, a finite number of S values are possible.
doi:10.1371/journal.pgen.1002101.g002
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signaling pathway appears to be significant. GnRH has been
linked with HR-positive breast cancer and the use of GnRH
analogues in breast cancer treatment has already been
proposed [42,43]. However, a recent large sequencing study
found no association of GnRH1 or GnRH receptor gene
polymorphisms with breast cancer risk [44], contrary to the
author’s hypothesis that common, functional polymorphisms of
GnRH1 and GnRHR could influence breast cancer risk by
modifying hormone production. In contrast to their null
findings, our result suggests that there are system-wide
variations in GnRH signalling that contribute to risk that are
not evident when considering the GnRH1 and GnRHR SNPs
independently.
Of the 1081 pathways considered, four–FGF signaling, MAPK
signaling, regulation of actin cytoskeleton, and prostate cancer–
contained FGFR2, the gene found to be significantly associated in
the initial CGEMS analysis [4]. However, only one–prostate
cancer–was significant in comparison to randomly generated
pathways of the same length. It may reasonably be asked, then,
whether the high significance of the prostate cancer pathway in
Table 2 is a result of FGFR2. To address this, we eliminated the
FGFR2 SNP from the prostate cancer pathway; the resampling-
based test remained significant (p(DSP)~0:044,OR~0:3,
q(OR)~ 8.2e-09), suggesting that the association of the prostate
cancer pathway is not driven solely by differences in FGFR2.
Liver cancer GWAS results
We carried out the same procedure in using data from the liver
cancer GWAS described above. Here, 1049 pathways were non-
trivially covered in the data set; 53079 SNPs in the data could be
associated with at least one of the pathways. Because these 53079
SNPs were associated with 3718 unique genes, 3718 were kept in
the analysis (the most significant SNP for each gene of interest).
The 1081 pathways ranged from 2 to 193 genes, with a mean of
16. As above, DSP scores for differential S distributions in cases
and controls were computed for each pathway, resampled p values
obtained for each pathway size, odds ratios for S were obtained,
and the multiple hypotheses were corrected using FDR adjustment
[37,38]. Significant pathways are listed in Table 3, and plots of the
top three pathways are given in Figure 4a–4d. As in the breast
cancer data above, we removed pathways which had over 60%
their SNPs covered by another pathway (a complete list, with
overlapping pathways, is give in Table S2) and examined the
correlation in S for all remaining pathways (maximum r~0:42).
The results here are interesting. First, we observe that a couple
pathways are significant in both the CGEMS breast and liver GWAS
with similar effect sizes, namely ErbB signaling and biosynthesis of
unsaturated fatty acids. ErbB has a well–established association with
cancer; unsaturated fatty acid biosynthesis may link diet to cancer
risk, and its appearance may suggest a gene-environment interaction.
The commonality of these known cancer-associated pathways across
the two studies suggest that there may exist genetic patterns that
Table 2. PID pathways with significant DSP in the CGEMS breast cancer GWAS.
Pathway Source Length DSP p(DSP) O.R. q(O.R.)
Purine metabolism Kegg 136 1.86 6.36e-03 1.59 4.15e-21
Calcium signaling pathway Kegg 100 1.38 1.82e-03 1.55 6.99e-20
Melanogenesis Kegg 84 2.36 4.55e-03 1.53 1.47e-18
Gap junction Kegg 80 1.54 5.45e-03 1.49 1.49e-16
ErbB signaling pathway Kegg 81 1.36 1.45e-02 1.46 4.68e-15
Long-term potentiation Kegg 60 1.71 9.09e-04 1.45 4.34e-15
GnRH signaling pathway Kegg 79 1.36 1.18e-02 1.44 1.32e-14
TCR signaling in naive CD4+ T cells NCI-Nature 60 2.11 5.45e-03 1.42 7.80e-13
Prostate cancer Kegg 75 1.45 4.09e-02 1.38 4.37e-11
PKC-catalyzed phosphorylation myosin phosphatase BioCarta 20 1.97 v1e-04 1.30 5.82e-09
CCR3 signaling in eosinophils BioCarta 21 1.59 1.09e-02 1.29 8.86e-08
Biosynthesis of unsaturated fatty acids Kegg 18 1.69 2.45e-02 1.26 1.38e-06
Attenuation of GPCR signaling BioCarta 11 1.75 1.09e-02 1.25 2.41e-06
Stathmin and breast cancer resistance to
antimicrotubule agents
BioCarta 18 1.84 4.82e-02 1.24 4.96e-06
Visual signal transduction: Cones NCI-Nature 20 1.56 4.73e-02 1.24 2.24e-06
Dentatorubropallidoluysian atrophy (DRPLA) Kegg 11 1.84 2.73e-03 1.24 2.24e-06
Intrinsic prothrombin activation pathway BioCarta 22 1.35 3.18e-02 1.23 4.61e-06
Eicosanoid metabolism BioCarta 19 1.69 1.91e-02 1.23 3.44e-06
Effects of botulinum toxin NCI-Nature 7 1.44 2.27e-02 1.20 3.50e-05
Activation of PKC through G-protein coupled receptors BioCarta 10 1.50 9.09e-03 1.20 8.42e-06
Streptomycin biosynthesis Kegg 9 1.36 3.55e-02 1.17 1.89e-04
PECAM1 interactions Reactome 6 2.70 5.45e-03 1.17 7.28e-05
HDL-mediated lipid transport Reactome 8 1.47 2.00e-02 1.14 1.59e-03
Granzyme A mediated apoptosis pathway BioCarta 8 1.97 1.73e-02 1.12 6.60e-04
(Pathways with over 60% SNPs covered by another pathway have been removed; for the complete list, see Table S1). Pathway-length based resampled p-values,
denoted p(DSP), are given for significant pathways, along with the odds ratios and associated FDRs for a logistic regression model.
doi:10.1371/journal.pgen.1002101.t002
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those shared in the breast cancer data, many of the other significant
pathways in the liver cancer data well known to be tumorassociated,
including cell adhesion molecules, Wnt signaling, c-Kit receptor, and
angiogenesis pathways, further supporting the notion that germline
genetic differencesin these mechanismscontributeto cancer risk. The
appearance of many neuronal pathways is also supported by our
understanding of carcinogenesis: thes contain well-known signal
transduction molecules including Ras and PKA that may both be
driving their conferring increased cancer risk and driving the
significance of the pathway [45].
Additionally, six of the 25 significant liver cancer pathways are
immune– and inflammation–related, namely, antigen processing
and presentation (two, with v60% overlap), classical complement
pathway, corticosteroids, IL12 signaling mediated by STAT4, and
NO2-dependent IL-12 pathway in NK cells. This is a particularly
interesting finding in light of the fact that the original analysis of the
liver data [36] suggested that altered T-cell activation plays a direct
role in the onset of liver cancer. The involvement of the immune
system in liver cancer development has been established in clinical
studies and research involving model organisms. Increased activity
of helper T-cells, which promote inflammation, is associated with
Figure 3. Four significant pathways in breast cancer data. Scatter plots of SY,P for each pathway are overlayed with boxplots are given in the
left panel; higher values of S indicate that the sample is closer to other cases than it is to other controls. Distributions of S for cases (red) and controls
(black) are given to the right. A significant shift toward higher S values is seen in the cases. Odds ratios and FDR-adjusted OR p values are given.
doi:10.1371/journal.pgen.1002101.g003
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of cytotoxic T-lymphocytes is suppressed in liver cancers [47,48].
The inflammatory immune response, mediated by interleukins, has
also been closely connected to liver cancers in mice [49] and
humans [50–52]. These findings, coupled with the observation of
several significant immune-related pathways in our data, are
suggestive of germline polymorphisms in immune response that
lead to hepatocellular carcinoma risk.
Combining pathways
In both the breast and liver cancer results, we see observe that
even though significant pathways yield between a 1.5 and 2.0-fold
increase in odds for each unit increase in S (over its typical range
of approximately –3 to 3), the cases and controls are not crisply
separable based on S values. These findings suggest that it may be
possible to combine pathways to yield a model that is more
predictive than a single pathway alone. However, the S values
must not simply be put into the regression model because the
overlap in pathways will result in some SNPs being double-
counted. Rather, we combine pathways by taking the union of
their SNPs, and recomputing the statistics. Doing this sequentially
for the top pathways in the order as listed in Table 2 and Table 3
yields the values given in Table 4 and Table 5, respectively.
Considerably higher ORs are obtained when combining the
significant pathways. An illustration of the case and control
distributions when using a ‘‘superpathway’’ comprised of the top
three pathways in the breast and liver data, respectively, is given in
Figure 5. These findings support the notion that the genomic
variation contributing to risk is spread over several mechanisms,
rather than being concentrated in a single gene.
Discussion
We have introduced the Pathways of Distinction analysis method
(PoDA) for identifying pathways which can be used to distinguish
between phenotype groups. PoDA identifies sets of SNPs in GWAS
studies for which cases and controls exhibit differential ‘‘closeness’’
to other cases and controls; that is, it permits one to infer whether
cases are more similar to other cases than are controls across a given
set of SNPs. Because PoDA is designed to detect the joint effects of
multiple SNPs, it presents an approach to GWAS analysis that
augments single-SNP or single-gene tests.
We applied PoDA to two GWAS data sets, with highly
promising results. In the breast cancer data, we found a number
of pathways which are known to play a role in cancers generally
and breast cancer specifically, suggesting that differences in these
mechanisms which confer disease risk may exist at the germline
DNA level. In the liver cancer data, we found an extreme
abundance of immune-related pathways, further corroborating the
known link between inflammation and hepatocellular carcinoma,
and bolstering the observation in [36] that germ-line differences in
immune function may play a role in liver carcinogenesis.
Table 3. PID pathways with significant DSP in the liver cancer GWAS.
Pathway Source Length DSP p(DSP) O.R. q(O.R.)
Cell adhesion molecules (CAMs) Kegg 86 1.57 9.09e-03 1.66 3.56e-13
ErbB signaling pathway Kegg 76 1.45 3.45e-02 1.61 2.59e-10
Signaling events mediated by Stem cell factor receptor (c-Kit) NCI-Nature 40 2.35 5.45e-03 1.58 7.31e-10
Neurotrophic factor-mediated Trk receptor signaling NCI-Nature 50 1.60 2.36e-02 1.55 2.49e-08
Lissencephaly gene (LIS1) in neuronal migration and development NCI-Nature 21 2.02 7.27e-03 1.52 1.44e-07
Angiopoietin receptor Tie2-mediated signaling NCI-Nature 40 2.36 1.36e-02 1.51 5.77e-08
Reelin signaling pathway NCI-Nature 28 1.62 5.45e-03 1.46 7.35e-08
Syndecan-4-mediated signaling events NCI-Nature 27 1.74 1.64e-02 1.46 1.19e-06
Galactose metabolism Kegg 19 1.65 2.27e-02 1.44 5.01e-06
Vibrio cholerae infection Kegg 35 1.84 2.64e-02 1.43 6.67e-07
Paxillin-independent events mediated by a4b1 and a4b7 NCI-Nature 19 2.14 1.00e-02 1.40 6.67e-07
Antigen processing and presentation Kegg 34 3.26 1.36e-02 1.40 3.71e-08
Corticosteroids and Cardioprotection BioCarta 21 1.98 3.55e-02 1.39 1.24e-05
Lissencephaly gene (Lis1) in neuronal migration and development BioCarta 15 1.60 1.36e-02 1.37 2.52e-05
IL12 signaling mediated by STAT4 NCI-Nature 25 1.93 4.55e-02 1.37 1.58e-05
Biosynthesis of unsaturated fatty acids Kegg 13 1.76 1.64e-02 1.36 6.44e-05
Growth hormone signaling pathway BioCarta 18 1.75 3.18e-02 1.36 7.46e-05
Canonical Wnt signaling pathway NCI-Nature 28 1.92 4.73e-02 1.35 9.36e-06
NO2-dependent IL-12 pathway in NK cells BioCarta 8 1.82 2.73e-03 1.32 5.83e-05
Signaling events mediated by HDAC Class III NCI-Nature 19 2.12 3.91e-02 1.32 4.19e-05
Removal of aminoterminal propeptides from c-carboxylated proteins Reactome 7 3.12 5.45e-03 1.29 8.46e-05
Aminophosphonate metabolism Kegg 13 1.91 3.36e-02 1.26 8.17e-04
Antigen processing and presentation BioCarta 6 2.61 1.82e-03 1.22 3.36e-05
Classical complement pathway BioCarta 12 2.27 1.55e-02 1.19 1.67e-04
Chylomicron-mediated lipid transport Reactome 7 1.94 3.27e-02 1.16 1.49e-02
(Pathways with over 60% SNPs covered by another pathway have been removed; for the complete list, see Table S2). Pathway-length based resampled p-values,
denoted p(DSP), are given for significant pathways, along with the odds ratios and associated FDRs for a logistic regression model.
doi:10.1371/journal.pgen.1002101.t003
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analysis techniques [18–21]. Unlike gene-set enrichment type
approaches [17–19], which search for an overabundance of
significant markers in a gene set of interest, PoDA finds both sets
containing highly significant markers as well as sets that have a
subtle but consistent pattern across all the markers in the set. This
permits the detection of pathways in which the joint action of
several alterations produce a phenotype and those for which any of
several possible alterations, none of them the dominant one, confer
predisposition to disease. Indeed, many of the pathways indicated
in our analysis of the breast cancer data (Table 2) were not
detected using SNP-set enrichment [17–19] (data not shown),
including the highly significant purine metabolism and GnRH
signaling pathways, both of which are biologically relevant (purine
metabolism has been implicated in cancers generally due to its role
in DNA and RNA synthesis [40], and GnRH has been shown to
be clinically important in breast and gynecological cancers [53]).
These pathways, along with others that were indicated using
PoDA but not enrichment analysis (data not shown), have a
statistically significant difference in case and control S distributions
and remain significant in comparison with randomly-generated
pathways of the same length.
Because PoDA effectively measures the closeness of each
individual to remaining cases and controls, it bears a conceptual
Figure 4. Four significant pathways in liver cancer data. Scatter plots of SY,P for each pathway are overlayed with boxplots are given in the
left panel; higher values of S indicate that the sample is closer to other cases than it is to other controls. Distributions of S for cases (red) and controls
(black) are given to the right. A significant shift toward higher S values is seen in the cases. Odds ratios and FDR-adjusted OR p values are given.
doi:10.1371/journal.pgen.1002101.g004
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[54,55], as well as to the distance-based feature selection
algorithms like Relief-F and its derivatives [25–28]. However, it
must be remembered that the goal of PoDA is to indicate
mechanisms that may be deleteriously hit at the genomic level even
when those hits are heterogeneous, whereas the goal of nearest-
centroid classifiers and Relief-F–type feature selection is to derive a
minimal set of markers that best classify cases and controls (and
thus are the most homogeneously hit). These approaches are
complementary, and one can easily envision an application in
which (e.g.) Relief-F is run within pathways that are highly
significant in the PoDA analysis in order to single out the SNPs
driving the effect. In fact, this approach may improve ReliefF’s
ability to find those genes, since the nearest neighbors from which
the Relief SNP weights are calculated would be the nearest-
neighbors for that specific pathway, thus discounting heterogeneity
introduced by mechanistically unrelated genes. For instance, in the
provided example (Figure 1), ReliefF fails to identify the
significance of SNPs 1–3 when run using the complete 50-SNP
data, but places at least two of SNPs 1, 2 or 3 in the top third of
selected features when restricted to SNPs 1–12.
While PoDA has many benefits, it should be noted that when
epistasis drives a phenotype with no differences in the minor allele
frequencies for the epistatically-interacting genes (as opposed to a
slight yet consistent one shown in the example), PoDA as
computed via Eqs. 1,2 will miss the pathway. Geometrically, such
a situation would mean that the case and control groups have the
same centroids while having a different distribution of samples
about those centroids. A famous example of this is provided
through the non-linearly separable XOR (exclusive or): consider
two epistatic loci (X,Y) such that all controls have genotypes in
the set f(0,0),(1,1)g and all cases have genotypes in the set
f(0,1),(1,0)g (i.e., that a genotype of 1 at either locus can be
compensated by a genotype of 1 at the other, but having just one
alone–1 at exclusively X or Y–is deleterious). If the loci X and Y
each have the same MAF in cases and controls, it is plain to see
that the centroids will be in the same location for both groups, and
Eq. 1 will yield zero for both cases and controls. If instead of using
Eq. 1, we compute pairwise sample-sample distances, we can
circumvent this limitation and find such epistatic situations (it is
this pairwise approach that permits Relief-F to also uncover
nonlinearly interacting SNPs). While we provide the facility for
this in the PoDA package, the cost of carrying out the pairwise
computation is a considerable increase in computational com-
plexity.
A number of potential avenues exist to extend the application of
PoDA further. One possible application is in improving the
reproducibility of GWAS results. We note that several of the pathways
identified in the breast cancer GWAS data were also implicated in the
liver cancer data, which suggests that there may be common features
which distinguish individuals to cancer generally. Because different
GWA studies–even those of the same phenotypes–often yield different
results at the SNP level, it may be possible to find common alterations
at the pathway level across disparate GWAS using PoDA.
Extending PoDA further, the DSP scores obtained for each
pathway may be examined for over-representation of extreme
values in pathways that comprise a particular biological subsystem–
one maythink of this as a ‘‘pathway-set’’enrichment analysis (which
Table 4. PoDA results for sucessive unions of significant
pathways in the CGEMS breast cancer data.
Pathway Length p(DSP) O.R. q(O.R.)
Top-2 318 v1e-04 2.02 1.63e-46
Top-3 397 1.00e-04 2.19 2.07e-54
Top-4 474 v1e-04 2.33 3.65e-62
Top-5 522 v1e-04 2.45 6.83e-66
Top-6 544 v1e-04 2.44 8.51e-66
Top-7 558 2.00e-04 2.47 1.22e-67
Top-8 626 v1e-04 2.59 1.01e-73
Top-9 658 v1e-04 2.64 9.84e-75
Top-10 700 v1e-04 2.77 9.72e-79
Top-11 710 v1e-04 2.80 1.42e-79
Top-12 723 v1e-04 2.82 2.06e-80
Top-13 739 v1e-04 2.89 3.31e-82
Top-14 744 v1e-04 2.93 2.86e-83
Top-15 770 v1e-04 2.96 6.41e-85
Top-16 774 v1e-04 2.97 5.10e-85
Top-17 791 v1e-04 2.95 2.43e-85
Top-18 800 v1e-04 3.06 1.15e-87
Top-19 814 v1e-04 3.14 1.19e-89
Top-20 832 v1e-04 3.26 4.51e-92
Top-21 837 v1e-04 3.28 2.92e-92
Top-22 839 v1e-04 3.29 2.41e-92
Top-23 845 v1e-04 3.34 1.45e-93
Top-24 854 v1e-04 3.38 4.62e-95
Pathway-length based resampled p values, denoted p(DSP), are given along
with the odds ratios and associated FDRs for a logistic regression model.
doi:10.1371/journal.pgen.1002101.t004
Table 5. PoDA results for sucessive unions of significant
pathways in the liver cancer data.
Pathway Length p(DSP) O.R. q(O.R.)
Top-2 321 5.38e-02 2.37 1.20e-27
Top-3 402 2.80e-03 2.63 1.40e-34
Top-4 474 1.10e-03 2.86 6.50e-38
Top-5 539 9.00e-04 3.22 4.03e-42
Top-6 560 1.00e-04 3.39 1.19e-43
Top-7 580 v1e-04 3.50 1.39e-44
Top-8 589 6.00e-04 3.50 1.35e-44
Top-9 603 4.00e-04 3.52 1.23e-44
Top-10 624 v1e-04 3.60 1.33e-45
Top-11 640 v1e-04 3.73 3.69e-47
Top-12 646 v1e-04 3.78 1.68e-47
Top-13 667 v1e-04 3.81 9.29e-48
Top-14 709 3.00e-04 3.88 1.90e-48
Top-15 751 v1e-04 4.09 2.11e-49
Top-16 761 v1e-04 4.09 1.76e-49
Top-17 797 v1e-04 4.45 1.29e-50
Top-18 805 v1e-04 4.46 5.24e-51
Top-19 823 v1e-04 4.56 2.20e-51
Top-20 838 v1e-04 4.56 1.73e-51
Pathway-length based resampled p values, denoted p(DSP), are given along
with the odds ratios and associated FDRs for a logistic regression model.
doi:10.1371/journal.pgen.1002101.t005
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GSEA [17]), and could use it to answer whether (e.g.) immune-
related pathways are hit in liver cancer more often than expected by
chance. Alternatively, boosting [56,57] could be used to find sets of
pathways which are more predictive of case status than individual
pathways. Either of these approaches would yield a richer, systems-
wide view of the connection between genotype and phenotype.
Finally, because PID contains topological information regarding
pathway connectivity, one may consider sub-networks of pathways,
permitting one to find potential chemopreventive and therapeutic
targets. Alternatively, Relief-F can be used, as mentioned above, in
a pathway–specific manner toyield the subset ofSNPs that drivethe
distinction of cases and controls in high-DSP pathways.
PoDA provides an advantage over existing GWAS analysis
methods. Because it does not rely on the significance of individual
markers, it has the power to aid in identifying the genomic causes
of complex diseases that would not be detected in single-gene tests
or enrichment analyses. The size of the SNP set is not limited in
PoDA, and since PoDA leverages known biological relationships to
find multi-SNP effects, the results are readily interpretable. PoDA
may thus be used to augment existing analysis techniques and
provide a richer, systems-level understanding of genomics.
Availability
R software to carry out the PoDA computation is available via
http://braun.tx0.org/PoDA.
Supporting Information
Table S1 Full list PID pathways with significant DSP in the
breast cancer GWAS, including highly ‘‘overlapping’’ pathways.
Pathway-length based resampled p-values, denoted p(DSP), are
given for significant pathways, along with the odds ratios and
associated FDRs for a logistic regression model.
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Table S2 Full list PID pathways with significant DSP in the liver
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